Similar herpes zoster incidence across Europe: results from a systematic literature review

BMC Infectious Diseases

Robert W Johnson¹  Hélène Bricout²  Ana M Cebrián-Cuenca⁴  Sybil Pinchinat³ 

[1] Department of Ophthalmology, University of Bristol, Bristol, UK;Epidemiology Department, Sanofi Pasteur MSD, 8 rue Jonas Salk, Lyon, 69007, France;Biostatem, Parc d’Activité Via Domitia, 205 Avenue des Gardians, Castries, 34160, France;Centro de Salud de Ayora, Avenida Argentina, Ayora, Valencia, 7 46620, Spain

关键词: Incidence;    Europe;    Shingles;    Herpes zoster;    Epidemiology;   

Others  :  1148947
DOI  :  10.1186/1471-2334-13-170

 received in 2012-10-29, accepted in 2013-03-06,  发布年份 2013

【 摘 要 】

Background

Herpes zoster (HZ) is caused by reactivation of the varicella-zoster virus (VZV) and mainly affects individuals aged ≥50 years. The forthcoming European launch of a vaccine against HZ (Zostavax®) prompts the need for a better understanding of the epidemiology of HZ in Europe. Therefore the aim of this systematic review was to summarize the available data on HZ incidence in Europe and to describe age-specific incidence.

Methods

The Medline database of the National Library of Medicine was used to conduct a comprehensive literature search of population-based studies of HZ incidence published between 1960 and 2010 carried out in the 27 member countries of the European Union, Iceland, Norway and Switzerland. The identified articles were reviewed and scored according to a reading grid including various quality criteria, and HZ incidence data were extracted and presented by country.

Results

The search identified 21 studies, and revealed a similar annual HZ incidence throughout Europe, varying by country from 2.0 to 4.6/1 000 person-years with no clearly observed geographic trend. Despite the fact that age groups differed from one study to another, age-specific HZ incidence rates seemed to hold steady during the review period, at around 1/1 000 children <10 years, around 2/1 000 adults aged <40 years, and around 1–4/1 000 adults aged 40–50 years. They then increased rapidly after age 50 years to around 7–8/1 000, up to 10/1 000 after 80 years of age. Our review confirms that in Europe HZ incidence increases with age, and quite drastically after 50 years of age. In all of the 21 studies included in the present review, incidence rates were higher among women than men, and this difference increased with age. This review also highlights the need to identify standardized surveillance methods to improve the comparability of data within European Union Member States and to monitor the impact of VZV immunization on the epidemiology of HZ.

Conclusions

Available data in Europe have shortcomings which make an accurate assessment of HZ incidence and change over time impossible. However, data are indicative that HZ incidence is comparable, and increases with age in the same proportion across Europe.

【 授权许可】

   
2013 Pinchinat et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Van Der Wielen M, Van Damme P: The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 2002, 161:588-593.
• [2]British Society for the Study of Infection: Guidelines for the management of shingles: report of a working group of the British Society for the Study Infection. J Infect 1995, 30:193-200.
• [3]Gross G, Schöfer H, Wassilew SW, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW: Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003, 26:277-289.
• [4]Lee VK, Simpkins L: Herpes Zoster and Postherpetic Neuralgia in the Elderly. Geriatr Nurs 2000, 21:132-136.
• [5]Edmunds WJ, Brisson M, Rose JD: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090.
• [6]Schmader K: Herpes Zoster in Older Adults. Clin Infect Dis 2001, 32:1481-1486.
• [7]Yawn BP, Saddier P, Wollan PC, Sauver JL, Kurland MJ, SY LS: A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction. Mayo Clin Proc 2007, 82:1341-1349.
• [8]Sengupta N, Breuer J: A Global Perspective of the Epidemiology and Burden of Varicella-Zoster Virus. Curr Ped Rev 2009, 5:207-228.
• [9]Hannouche D, Alfandari S, Bouhour D, Fouchard N, Geffray L, Quinet B: Prise en charge des infections à VZV. Med Mal Infect 1998, 28:1-8. Article in French
• [10]Johnson RW, Wasner G, Saddier P, Baron R: Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007, 7:1581-1595.
• [11]Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, Breuer J: A Study of Shingles and the Development of Postherpetic Neuralgia in East London. J Medl Virol 2003, 70:S24-S30.
• [12]Scott FT, Johnson RW, Leedham-Green ME, Davies E, Edmunds WJ, Breuer J: The burden of Herpes Zoster: A prospective population based study. Vaccine 2006, 24:1308-1314.
• [13]Moher D, Liberati A, Tetzlaff J, Altman DG: Reprint–preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 2009, 89:873-880.
• [14]Meister W, Neiss A, Gross G, Doerr HW, Höbel W, Malin JP, Von Essen J, Reimann BY, Witke C, Wutzler P: Demography, Symptomatology, and Course of Disease in Ambulatory Zoster Patients. Intervirol 1998, 41:272-277.
• [15]Chidiac C, Bruxelle J, Daurès J-P, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, De Labaryere C: Characteristics of Patients with Herpes Zoster on Presentation to Practitioners in France. Clin Infect Dis 2001, 33:62-69.
• [16]di Luzio PU, Arpinelli F, Visonà G: Herpes Zoster and its Complications in Italy: An Observational Survey. J Infect 1999, 38:116-120.
• [17]Gabutti G, Serenelli C, Sarno O, Marconi S, Corazza M, Virgili A: Epidemiologic features of patients affected by herpes zoster: database analysis of the Ferrara University Dermatology Unit, Italy. Méd Maladies Infect 2010, 40:268-272.
• [18]Parlato A, Spica VR, Ciccozzi M, Farchi F, Gallè F, Di Onofrio V, Franco E, Liguori G: Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy. BMC Public Health 2010, 10:1-5. BioMed Central Full Text
• [19]Pérez-Faérinos N, Ordobas M, Garcia-Fernandez C, Garcia-Comas L, Canellas S, Rodero I, Gutiérrez-Rodriguez A, Garcia-Gutiérrez J, Ramirez R: Varicella and Herpes Zoster in Madrid, based on the Sentinel General Practitioner Network: 1997–2004. BMC Infect Dis 2007, 7:1-5. BioMed Central Full Text
• [20]Truyers C, Bartholomeeusen S, Buntinx F, De Loof J: Incidentie van herpes zoster. Huisarts Onderzoek 2005, 34:260-262. Article in Flemish
• [21]Réseau Sentinelles Coordination nationale: Bilan annuel du réseau Sentinelles Janvier-Décembre 2009. Rapport d’activité. Paris: ; 2009.
• [22]Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O, Blanchon T, Hanslik T: Herpes zoster: Burden of disease in France. Vaccine 2010, 28:7933-7938.
• [23]Mick G, Gallais JL, Simon F, Pinchinat S, Bloch K, Beillat M, Serradell L, Derrough T: Burden of Herpes Zoster and postherpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over. Rev Epidemiol Sante Publique 2010, 58:393-401. Article in French
• [24]Czernichow S, Dupuy A, Flahault A, Chosidow O: Zona: enquête d’incidence chez les médecins généralistes du réseau “Sentinelles”. Ann Dermatol Venereol 2001, 128:497-501. Article in French
• [25]Schiffner-Rohe VJ, Jow S, Lilie HM, Köster I, Schubert I: Herpes Zoster in Germany. A retrospective analyse of SHL data. MMW Fortschr Med 2010, 151(4):193-197. Article in German
• [26]Paul E, Thiel T: Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 1996, 47:604-609. Article in German
• [27]Helgason S, Sigurdsson JA, Gudmundsson S: The Clinical Course of Herpes Zoster: a Prospective Study in Primary Care. Eur J Gen Pract 1996, 2:12-16.
• [28]Petursson G, Helgason S, Gudmundsson S, Sigurdsson JA: Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998, 17:905-908.
• [29]Emberti Gialloreti L, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, Di Marzo R, Volpi A: Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. BMC Infect Dis 2010, 10:1-11. BioMed Central Full Text
• [30]Di Legami V, Gianino MM, Ciofi Degli Atti M, Massari M, Migliardi A, Scalia Tomba G, Zotti C: Epidemiology and costs of herpes zoster: Background data to estimate the impact of vaccination. Vaccine 2007, 25:7598-7604.
• [31]Opstelten W, Van Essen GA, Schellevis FG, Verheij TJM, Moons KGM: Gender as an Independent Risk Factor for Herpes Zoster: A Population-Based Prospective Study. Ann Epidemiol 2006, 16:692-695.
• [32]de Melker H, Berbers G, Hahné S, Rümke H, van den Hof S, de Wit A, Boot H: The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006, 24:3946-3952.
• [33]Opstelten W, Mauritz JW, De Wit NJ, Van Wijck AJM, Stalman WAB, Van Essen GA: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002, 19:471-475.
• [34]Cebrian-Cuenca AM, Diez-Domingo J, Puig-Barbera J, Navarro-Perez J, Sanmartin-Rodriguez M: Epidemiology of Herpes Zoster Infection among Patients Treated in Primary Care Centres in the Valencian Community (Spain). BMC Fam Pract 2010, 11:1-23. BioMed Central Full Text
• [35]Garcia Cenoz M, Castilla J, Montes Y, Moran J, Salaberri A, Elia F, Floristan Y, Rodrigo I, Irisarri F, Arriazu M, Zabala A, Barricarte A: Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005–2006. An Sist Sanit Navar 2011, 30:71-80.
• [36]Richard J-L, Zimmermann H: Herpès zoster 1998 – 2001. : Sentinella-Jahresbericht; 2001. 6. Article in French
• [37]Gauthier A, Breuer J, Carrington D, Martin M, Rémy V: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137:38-47.
• [38]Hope-Simpson RE: The Nature of Herpes Zoster: A Long-term Study and a New Hypothesis. Proc R Soc Med 1965, 58:9-20.
• [39]Fleming DM, Cross KW, Cobb WA, Chapman RS: Gender difference in the incidence of shingles. Epidemiol Infect 2003, 132:1-5.
• [40]Brisson M, Edmunds WJ: Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol 2003, 70:S9-S14.
• [41]Glynn C, Crockford G, Gavaghan D, Cardno P, Price D, Miller J: Epidemiology of shingles. J Roy Soc Med 1990, 83:617-619.
• [42]Eurostat: Population at 1 January. http://epp.eurostat.ec.europa.eu/ webcite
• [43]Volpi A, Gross G, Hercogova J, Johnson RW: Current Management of Herpes Zoster: The European View. Am J Clin Dermatol 2005, 6:317-325.
• [44]Donahue JG, Choo PW, Manson JE, Platt R: The Incidence of Herpes Zoster. Arch Intern Med 1995, 155:1605-1609.
• [45]Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO: Population-based study of herpes zoster and its sequelae. Medicine 1982, 61:310-316.
• [46]Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, Lewden L, Pinchinat S, Derrough T, Sana C, Caulin E, Soubeyrand B: Does monastic life predispose to the risk of Saint Anthony’s fire (herpes zoster)? Clin Infect Dis 2011, 53:405-410.
• [47]Floret D: Immunisation against varicella. Therapie 2005, 60:275-282.
• [48]Terada K, Yoshihiro K, Kawano S, Morita T: Incidence of herpes zoster in pediatricians and family practitioners. Estimation of efficacy of varicella vaccine for protection against herpes zoster in the elderly. Kawasaki Med J 1994, 20:99-102.
• [49]Brisson M, Gay NJ, Edmunds WJ, Andrews NJ: Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20:2500-2507.
• [50]Thomas SL, Wheeler JG, Hall AJ: Contacts with varicella or with children and protection against herpers zoster in adults:a case-control study. Lancet 2002, 360:678-682.
• [51]Salleras M, Dominguez A, Soldevila N, Prat A, Garrido P, Torner N, Borras E, Salleras L: Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 2011, 29:7602-7605.
• [52]Garnett GP, Grenfell BT: The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 1992, 108:513-528.
• [53]Yawn BP, Wollan P, St Sauver J: Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 2011, 174:1054-1061.
• [54]Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004, 1:26-33.
• [55]Pinot de Moira A, Nardone A: Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill 2005, 10:43-45.
• [56]Report Venice II: Varicella and herpes Zoster surveillance and vaccination recommandations 2010–11. Stockholm: ECDC; 2010.
• [57]Report Statens Serum Institut: Surveillance of Varicella and Herpes Zoster in Europe. Copenhagen: ; 2010.
• [58]Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF: Incidence of herpes-zoster, before and after varicella vaccination associated decreases in the incidence of varicella, 1992–2002. J Infect Dis 2005, 191:2002-2007.
• [59]Alain S, Paccalin M, Larnaudie S, Perreaux F, Launay O: Impact of routine pediatric varicella vaccination on the epidemiology of herpes zoster. Med Mal Infect 2009, 39:698-706. Article in French
• [60]Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, Seward JF: The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005, 5(68):1-9.
• [61]Eurostat: Active ageing and solidarity between generations. A statistical portrait of the European Union 2012. 2012 edition. Luxembourg: Luxembourg; 2012.
• [62]Jumaan A, Schmid DS, Gargiullo P, Seward J: Letter to the Editor. Vaccine 2004, 22:3228-3231.
• [63]Joesoef MR: Potential coding error of herpes zoster (HZ) vaccination and HZ diagnosis in administrative data. Vaccine 2011, 29:2008-2009.
• [64]Brisson M, Edmunds WJ, Law B, Gay NJ, Wall R, Brownell M, Roos L, De Serres G: Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001, 127:305-314.